Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review

Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review

  • Products Id :- GDPH194377FSA
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Epizyme Inc (EPZM)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.


Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. The company discovers and develops small molecule inhibitors of a class of enzymes, namely, histone methyl transferases (HMTs) and other chromatin modifying proteins (CMPs). Using its proprietary platform and collaborations, the company has initiated the identification and development of small molecule inhibitors of CMPs and HMTs. The company is developing product candidates for the treatment of solid tumors, non-hodgins lymphoma, mesothelioma, ovarian cancer, molecularly targeted tumors and sickle cell disease. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc Key Recent Developments

Aug 02,2018: Epizyme reports second quarter 2018 financial results and provides business updates

Jul 23,2018: Epizyme names Dr. Shefali Agarwal as Chief Medical Officer

May 08,2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates

Mar 13,2018: Epizyme Reports Fourth Quarter and Full Year 2017 Financial Results

Mar 12,2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Epizyme Inc-Key Facts 6

Epizyme Inc-Key Employees 7

Epizyme Inc-Key Employee Biographies 8

Epizyme Inc-Major Products and Services 9

Epizyme Inc-History 10

Epizyme Inc-Company Statement 12

Epizyme Inc-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 15

Company Overview 15

Epizyme Inc-Business Description 16

R&D Overview 16

Epizyme Inc-Corporate Strategy 17

Epizyme Inc-SWOT Analysis 18

SWOT Analysis-Overview 18

Epizyme Inc-Strengths 18

Epizyme Inc-Weaknesses 19

Epizyme Inc-Opportunities 20

Epizyme Inc-Threats 21

Epizyme Inc-Key Competitors 22

Section 3-Company Financial Ratios 23

Financial Ratios-Capital Market Ratios 23

Financial Ratios-Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Epizyme Inc, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Aug 02, 2018: Epizyme reports second quarter 2018 financial results and provides business updates 32

May 08, 2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates 34

Mar 12, 2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors 36

Nov 01, 2017: Epizyme Reports Third Quarter 2017 Operating Results and Company Updates 37

Aug 15, 2017: Epizyme Announces Leadership Transition for Finance Organization 38

Aug 04, 2017: Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress 39

May 08, 2017: Epizyme Reports First Quarter 2017 Results and Provides Corporate Update 41

Mar 09, 2017: Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals 42

Mar 09, 2017: Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company 44

Feb 07, 2017: Epizyme Elects Kevin Conroy to its Board of Directors 45

Section 6-Appendix 46

Methodology 46

Ratio Definitions 46

About GlobalData 50

Contact Us 50

Disclaimer 50

List of Figures

Epizyme Inc, Performance Chart (2013-2017) 26

Epizyme Inc, Ratio Charts 28

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

List of Tables

Epizyme Inc, Key Facts 6

Epizyme Inc, Key Employees 7

Epizyme Inc, Key Employee Biographies 8

Epizyme Inc, Major Products and Services 9

Epizyme Inc, History 10

Epizyme Inc, Subsidiaries 14

Epizyme Inc, Key Competitors 22

Epizyme Inc, Ratios based on current share price 23

Epizyme Inc, Annual Ratios 24

Epizyme Inc, Annual Ratios (Cont...1) 25

Epizyme Inc, Interim Ratios 27

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

Epizyme Inc, Recent Deals Summary 31

Currency Codes 46

Capital Market Ratios 46

Equity Ratios 47

Profitability Ratios 47

Cost Ratios 48

Liquidity Ratios 48

Leverage Ratios 49

Efficiency Ratios 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Takeda Pharmaceutical Co Ltd

Pfizer Inc

Novartis AG

Merck & Co Inc

Daiichi Sankyo Co Ltd

Constellation Pharmaceuticals Inc

AbbVie Inc

Epizyme Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8924
Site License
USD 250 INR 17848
Corporate User License
USD 375 INR 26771



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com